The French pharmaceutical giant will work with Novavax to commercialize its existing COVI-19 vaccine and help develop a new combined vaccine for both COVID-19 and Influenza
[stock-market-ticker symbols="AAPL;MSFT;GOOG;HPQ;^SPX;^DJI;LSE:BAG" stockExchange="NYSENasdaq" width="100%" palette="financial-light"]
